An academia-driven compassionate use program for patients with recurrent H3K27-altered diffuse midline glioma: a new way to access innovation when clinical trials are lacking.

Subjects

Subjects :

Humans
Compassionate Use Trials
Mutation
Brain Neoplasms drug therapy
Brain Neoplasms genetics
Glioma drug therapy
Glioma genetics

Details

Language :

English

ISSN :

1569-8041

Volume :

34

Issue :

9

Database :

MEDLINE

Journal :

Annals of oncology : official journal of the European Society for Medical Oncology

Publication Type :

Editorial & Opinion

Accession number :

37423297

Full Text :

https://doi.org/10.1016/j.annonc.2023.06.012